Cancer Genetics, Inc (CGI) is a privately held company based in Rutherford, NJ with offices in Milan, Italy. CGI has a synergistic business model comprised of a clinical reference laboratory focused on state-of-the-art oncology testing, which is CLIA and CAP accredited, and a division that develops molecular diagnostic products for hematological malignancies, urogenital cancers, and HPV-associated cancers. Major shareholders include the founders of CGI, and Pappajohn Capital.
No public market currently exists for their common stock. This would be an initial public offering of 5,000,000 shares of common stock. They anticipate that the initial public offering price per share of the common stock will be between $6.00 and $8.00 per share.
The company agreed to form a joint venture with Mayo in March 2013 that will focus on developing oncology diagnostic services and tests utilizing next-generation sequencing.